Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cue Biopharma Inc CUE

Healthcare Biotechnology
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease... see more

Recent & Breaking News (NDAQ:CUE)

Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University

GlobeNewswire May 14, 2020

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire May 12, 2020

Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer

GlobeNewswire April 20, 2020

Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

GlobeNewswire March 17, 2020

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire March 10, 2020

Cue Biopharma to Present at Upcoming Investor Conferences in March 2020

GlobeNewswire February 26, 2020

Cue Biopharma's Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit

GlobeNewswire February 19, 2020

Cue Biopharma to Present at the Biomarkers Series UK

GlobeNewswire February 12, 2020

Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies

GlobeNewswire January 21, 2020

Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress

GlobeNewswire December 2, 2019

Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights

GlobeNewswire November 12, 2019

Cue Biopharma to Present at Upcoming Investor Conferences in November 2019

GlobeNewswire November 6, 2019

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire November 5, 2019

Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

GlobeNewswire October 30, 2019

Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center

GlobeNewswire October 15, 2019

Cue Biopharma Announces Changes to its Board of Directors

GlobeNewswire October 9, 2019

Cue Biopharma to Present at Upcoming October 2019 Scientific Conferences

GlobeNewswire October 9, 2019

Cue Biopharma Promotes Dr. Anish Suri to President and CSO

GlobeNewswire October 7, 2019

Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference

GlobeNewswire October 2, 2019

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma

GlobeNewswire September 30, 2019